Industry Liaison Forum (ILF)
MISSION: Promote and facilitate the contribution of the biomedical industry to the global HIV response, focusing on expediting development and approval of HIV diagnostics and medicines.
The past decade has been marked by rapid advances in HIV research, leading to the introduction of new and more efficacious and client-friendly interventions for treating people living with HIV and preventing the further spread of the virus. Critical gaps remain in the development and expedient delivery of medical innovations to the people who most need them across the HIV cascade. The IAS Industry Liaison Forum (ILF) works to promote and facilitate the full contribution of the biomedical industry to the global HIV response by catalysing dialogue, engagement and action to address barriers along the HIV care continuum. The ILF brings to the foreground the contribution of an interdisciplinary group on key thematic topics.
The ILF builds on its collaboration platform to address a range of pertinent issues, including:
- Paediatric HIV
Fast track the development of paediatric HIV medicines (focusing on the most-needed paediatric ARV formulations).
- Regulatory Affairs
Improve regulatory approval processes for timely access to quality HIV diagnostics and medicines by populations most in need.
This work is guided by a multi-stakeholder ILF Advisory Group made up of representatives from the HIV biomedical industry, as well as people outside this industry.
Learn more about the ILF Advisory Group, the corporate partnership programme and ILF guidance on compliance with competition rules.
As of the end of 2016, there were more than two million children (ages 0-14) living with HIV globally. Without treatment, a third of HIV-infected children will die in their first year of life, and half before their second birthday. Yet, the availability of ARV formulations adapted to paediatric needs is severely lagging behind that of adult treatments – and the younger the child, the fewer the number of adapted ARV formulations. Consequently, among the 50% children living with HIV globally who were receiving ARV therapy in 2015, much fewer received optimal formulations adapted to their needs.
Overlapping regulatory requirements globally and across countries (including WHO Prequalification and national regulatory agencies) frequently require companies to conduct additional, sometimes duplicative, clinical trials and file multiple and different applications. In addition, some regulatory processes are inefficient, and their timelines are not always transparent. These issues lead to increases in development costs and delays before new diagnostic tools and medicines can be registered and used in country. Simplification and improvement of existing processes therefore represent opportunities to fast track access to quality diagnostics and medicines.
Advance procurement policies have the potential to provide a minimum guaranteed market after the development of specific, highly-needed paediatric ARV formulations. This approach has been successfully used in the vaccine field and should be considered as a pragmatic approach to incentivise development of priority paediatric ARV formulations by reducing market uncertainty. Through its work, the ILF will advocate for large ARV buyers to consider advance procurement of priority paediatric ARV formulations in their efforts to provide quality care to this neglected population.
Inefficiencies in regulatory systems can cause both delayed introduction of medical innovations onto the market and reduced access to those innovations for people who could benefit from them the most. The ILF is working to assess the WHO Prequalification of In Vitro Diagnostics and Medicines Programmes, as well as increase transparency of the programmes’ timelines from submission to final approval of commodities. Through this work, the ILF will advocate for improvements to these processes and increased transparency over their implementation.
Limited treatment options and sub-optimal formulations have contributed to poor adherence and outcomes for children living with HIV. Despite the need for expanded and improved options for paediatric treatment, which are essential for sustained adherence and better treatment outcomes, barriers to incentivizing research and development remain. The Global Accelerator for Paediatric Formulations (GAP-f) aims to promote a faster, more efficient and more focused approach to paediatric formulation development. It is a collaborative framework that can help get better paediatric products quicker and cheaper by prioritizing products, streamlining the generation of clinical evidence, incentivizing manufacturers, accelerating product development and introduction, and coordinating procurement. The GAP-f formalizes collaboration across sectors to ensure accelerated development and uptake of the most needed drugs and formulations for children.
Ensuring, early on, that various industry perspectives are included in the development of the global accelerator is critical, as industry’s involvement is essential for the success of this initiative. The ILF leads this inclusion of the industry perspective in the development of a Global Accelerator for Paediatric Formulations (GAP-f), in collaboration with partner organizations.
During the 1994 Paris AIDS Summit, 42 countries declared the Greater Involvement of People living with HIV/AIDS (GIPA) as a cornerstone of the HIV response. Many stakeholders in HIV have found innovative ways to involve a diverse range of PLHIV and this has contributed to strengthened and improved responses acting on the links between HIV and human rights. GIPA has thereby contributed to addressing stigma and discrimination. Looking back, GIPA means two things:
- The recognition that PLHIV have intimate knowledge of factors making people and communities vulnerable to HIV, as well as first-hand experience of the realities of living with HIV
- The creation of meaningful spaces within every aspect of the HIV response to include PLHIV in decision-making processes that affect their lives.
Engaging affected communities
Grounded in the belief that the GIPA principle promotes and guides the substantial and meaningful engagement of PLHIV at all levels of the HIV response, it is opportune to consider how deeply and widely GIPA is understood and implemented. To take stock of the implementation of GIPA across the HIV biomedical industry sector in particular, the ILF has explored to what extent the GIPA principle is being implemented in the biomedical industry involved in HIV and associated diseases.
ILF Corporate Partners
The Industry Liaison Forum would like to thank its 2017 Corporate Partners:
See the list of previous industry partners | Learn about the ILF Corporate Partnership Programme